Valganciclovir HCl is an antiviral drug. This was found in 2 polymorphic forms, i.e. amorphous and crystalline form. In market valganciclovir HCl crystalline form tablet is available, which is manufactured and marketed by Roche. And Roche having patent on valganciclovir HCl, which was approved on 29 march 2001 and patent expire on 29 march 2015. Many pharmaceutical company researches were going on valganciclovir HCL amorphous form tablet development. The main objective of studying different polymorphs of Valganciclovir HCl and Paracetamol was to identify suitable polymorphic form for development of stable and effective dosage form. Another objective to find out the suitable tablet preparation method for valganciclovir HCl semi-amorphous form. In preparation of valganciclovir HCl semi-amorphous form tablet was found that direct compression & wet-granulation method are not suitable method. Because after direct compression & wet-granulation semi-amorhous form converted into crystalline form. slugging method was most suitable method for development of valganciclovir HCl semi-amorphous tablet.
Loading....